CA2942641A1 - Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor - Google Patents

Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor Download PDF

Info

Publication number
CA2942641A1
CA2942641A1 CA2942641A CA2942641A CA2942641A1 CA 2942641 A1 CA2942641 A1 CA 2942641A1 CA 2942641 A CA2942641 A CA 2942641A CA 2942641 A CA2942641 A CA 2942641A CA 2942641 A1 CA2942641 A1 CA 2942641A1
Authority
CA
Canada
Prior art keywords
pain
pharmaceutically acceptable
naltrexone
composition
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2942641A
Other languages
English (en)
French (fr)
Inventor
Annette Channa Toledano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allodynic Therapeutics LLC
Original Assignee
Allodynic Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/799,287 external-priority patent/US20130310412A1/en
Priority claimed from US13/837,099 external-priority patent/US9095548B2/en
Priority claimed from US13/841,100 external-priority patent/US9205081B2/en
Priority claimed from US13/851,267 external-priority patent/US20150111916A9/en
Priority claimed from US13/851,773 external-priority patent/US20150111917A9/en
Application filed by Allodynic Therapeutics LLC filed Critical Allodynic Therapeutics LLC
Publication of CA2942641A1 publication Critical patent/CA2942641A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2942641A 2013-03-13 2014-03-13 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor Abandoned CA2942641A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US13/799,287 2013-03-13
US13/799,287 US20130310412A1 (en) 2010-06-28 2013-03-13 Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
US13/837,099 2013-03-15
US13/841,100 2013-03-15
US13/837,099 US9095548B2 (en) 2010-04-29 2013-03-15 Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
US13/841,100 US9205081B2 (en) 2010-04-29 2013-03-15 Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
US13/851,773 2013-03-27
US13/851,267 2013-03-27
US13/851,267 US20150111916A9 (en) 2010-04-29 2013-03-27 Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
US13/851,773 US20150111917A9 (en) 2010-04-29 2013-03-27 Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain
PCT/US2014/025771 WO2014160077A1 (en) 2013-03-13 2014-03-13 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor

Publications (1)

Publication Number Publication Date
CA2942641A1 true CA2942641A1 (en) 2014-10-02

Family

ID=51625328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942641A Abandoned CA2942641A1 (en) 2013-03-13 2014-03-13 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor

Country Status (5)

Country Link
EP (1) EP2968293A4 (https=)
JP (1) JP2016512561A (https=)
AU (1) AU2014244152A1 (https=)
CA (1) CA2942641A1 (https=)
WO (1) WO2014160077A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105449A1 (en) * 2014-12-22 2016-06-30 Seth Lederman Compounds for use as pain therapeutics
CN108369222B (zh) * 2015-08-31 2021-06-04 明尼苏达大学董事会 阿片受体调节剂及其用途
JP7029400B2 (ja) * 2016-09-09 2022-03-03 武田薬品工業株式会社 環状化合物
US20180147201A1 (en) 2016-10-31 2018-05-31 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2025259600A2 (en) * 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1041987B1 (en) * 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
WO2004071423A2 (en) * 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
JP2006131545A (ja) * 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
ES2620672T3 (es) * 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2011087755A2 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20110269727A1 (en) * 2010-04-29 2011-11-03 Toledano Annette C Composition to reduce allodynic back pain and related method of use
US20130189354A1 (en) * 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy

Also Published As

Publication number Publication date
AU2014244152A1 (en) 2015-10-01
EP2968293A1 (en) 2016-01-20
WO2014160077A1 (en) 2014-10-02
JP2016512561A (ja) 2016-04-28
EP2968293A4 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
Pergolizzi et al. The pharmacological management of dental pain
Menhinick et al. The efficacy of pain control following nonsurgical root canal treatment using ibuprofen or a combination of ibuprofen and acetaminophen in a randomized, double‐blind, placebo‐controlled study
Mehlisch The efficacy of combination analgesic therapy in relieving dental pain
Ezri et al. Topical Nifedipinevs. Topical Glyceryl Trinitrate for Treatment of Chronic Anal Fissure
Cordell et al. Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic
JP6014702B2 (ja) 線維筋痛症候群の長期治療のためのミルナシプラン
AU2022203543A1 (en) Methods of treating inflammation or neuropathic pain
CA2942641A1 (en) Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor
JP2020073563A (ja) 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物
Ventafridda et al. Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs
Kaur et al. Antidepressants as antipruritic agents: a review
US20040258740A1 (en) Transdermal delivery composition
WO2013063263A1 (en) Pharmaceutical compositions for treating pain
CA2926389A1 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
ES2626651T3 (es) Composiciones para el tratamiento de la fatiga crónica
Engindeniz et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double–blind study
McCarberg Overview and treatment of opioid-induced constipation
AU2021388141A9 (en) Treatment of raynaud's disease
US20130310412A1 (en) Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
MX2007006091A (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante.
EP2432319A1 (en) Method of treatment of obsessive compulsive disorder with ondansetron
Mehlisch et al. Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial
Basile et al. Identifying and managing factors that interfere with or worsen blood pressure control
CN1447693A (zh) 血管紧张素ii拮抗剂的新用途
TW200911225A (en) Methods for improving physical function in fibromyalgia

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200313